Management of Intensive Care Unit of the Case with Toxic Epidermal Necrolysis
PDF
Cite
Share
Request
Case Report
P: 187-190
December 2018

Management of Intensive Care Unit of the Case with Toxic Epidermal Necrolysis

Turk J Dermatol 2018;12(4):187-190
1. İstanbul Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi, Anestezi ve Reanimasyon Kliniği, İstanbul, Türkiye
No information available.
No information available
Received Date: 11.06.2014
Accepted Date: 31.10.2014
Publish Date: 30.11.2018
PDF
Cite
Share
Request

ABSTRACT

Toxic epidermal necrolysis (TEN) is a severe autoimmune idiosyncratic reaction, which is mostly caused by drugs, involves for more than 30% of the body surface and affects the entire mucosa, and is characterized by extensive epidermal loss. The worldwide incidence of TEN is estimated to be 0.4-1.3 million. The mortality rate of TEN is between 30-50%, and primary death cause is septicemia and multiple organ failure. The Scorten Mortality Scoring is widely used in assay of mortality and morbidity and gives substantially correct results. Since lesions are similar with burns and the possibility of sepsis in TEN, their follow-up in the burn intensive care unit (BICU) is widely accepted. In this case report, a 30-year-old male patient who developed TEN on the third day of cefuroxime axetil oral use due to upper respiratory tract infection was presented in the BICU follow-up, in company with the literature data.

References

1Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-61.
2Friedmann PS, Leew MS, Friedmann AC, et al. Mechanisms in cutaneous drug hypersensitivity reactions. Clin Exp Allergy 2003;33:861-72.
3Sever C, Kulahçı Y, Öksüz S, ve ark. Amoksisilinin Neden Olduğu Toksik Epidermal Nekroliz. J Clin Anal Med 2011;2:121-3.
4Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53.
5Struck MF, Hilbert P, Mockenhaupt M, et al. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med 2010;36:22-32.
6Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res 2008;29:706-12.
7Keskin Ö, Yıldırım İ, Kalemoğlu M, ve ark. Naproksen Sodyum Kullanımı Sonucu Gelişen Toksik Epidermal Nekroliz Olgusu. Nobel Med 2005;1:28-31.
8Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res 2008;29:706-12.
9Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008;29:269-76.
10Nagy N, McGrath JA. Blistering skin diseases: a bridge between dermatopathology and molecular biology. Histopathology 2010;56:91-9.
11Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-61.
12Yavuz C, Gürgey E. Toksik epidermal nekrozda tedavi yaklaşımları. Türkiye klinikleri Dermatol 2006;16:59-68.
13Dicle Ö, Yılmaz E, Alpsoy E. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Evaluation. Turkderm 2009;43:15-20.
Article is only available in PDF format. Show PDF
2024 ©️ Galenos Publishing House